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Limited HIV-1 Reactivation in 
Resting CD4+ T cells from Aviremic 
Patients under Protease Inhibitors
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Carine Van Lint2,* & Georges Herbein1,*
A latent viral reservoir that resides in resting CD4+ T cells represents a major barrier for eradication of 
HIV infection. We test here the impact of HIV protease inhibitor (PI) based combination anti-retroviral 
therapy (cART) over nonnucleoside reverse transcriptase inhibitor (NNRTI)-based cART on HIV-1 
reactivation and integration in resting CD4+ T cells. This is a prospective cohort study of patients with 
chronic HIV-1 infection treated with conventional cART with an undetectable viremia. We performed 
a seven-year study of 47 patients with chronic HIV-infection treated with cART regimens and with 
undetectable plasma HIV-1 RNA levels for at least 1 year. Of these 47 patients treated with cART, 
24 were treated with a PI-based regimen and 23 with a NNRTI-based regimen as their most recent 
treatment for more than one year. We evaluated the HIV-1 reservoir using reactivation assay and 
integrated HIV-1 DNA, respectively, in resting CD4+ T cells. Resting CD4+ T cells isolated from PI-
treated patients compared to NNRTI-treated patients showed a limited HIV-1 reactivation upon T-cell 
stimulation (p = 0·024) and a lower level of HIV-1 integration (p = 0·024). Our study indicates that PI-
based cART could be more efficient than NNRTI-based cART for limiting HIV-1 reactivation in aviremic 
chronically infected patients.
Among the main features of human immunodeficiency virus-1 (HIV-1) infection are immune suppression and 
viral persistence1. Combination anti-retroviral therapy (cART) drives the viral load down to undetectable levels2. 
However, using the ultrasensitive assays, low levels of active viral replication can be detected in the majority of 
subjects successfully treated with cART3. Indeed, the persistence of latent reservoirs of replication-competent 
proviruses remains a major obstacle in HIV-1 eradication4,5. Latent reservoirs are established early during acute 
viral infection and include among others, macrophages and latently infected resting CD4+ T cells, these later 
being the main viral reservoir6–8.
Most of the studies so far have addressed the effect of cART on the decrease of HIV-1 viremia under limit of 
detection using the classical assays. Usually, a better virologic performance of nonnucleoside reverse transcriptase 
inhibitor-(NNRTI)-based cART compared to protease inhibitor-(PI)-including regimens has been reported9. 
Although PI-based regimen have lower rates of HIV suppression compared with the NNRTI-based treatments, 
greater CD4 cell increases are seen in patients on PI arm and there is also less development of major drug resist-
ance mutations in patients failing PI-based therapy10,11. Recently, cART intensification was assessed and did not 
reduce residual HIV-1 viremia in patients on cART, indicating that its potential to eradicate the virus appears 
limited12.
In contrast to the measurement of viremia in patients on cART, the impact of cART on the size of the cellular 
reservoirs of HIV-1 has been much less studied. Initiation of cART during primary HIV infection may limit the 
establishment of viral reservoirs, and very early cART limits the seeding of the HIV reservoir in long-lived central 
memory CD4+ T cells6,13,14. By contrast, the impact of cART on the HIV reservoir especially on viral reactivation 
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from resting CD4+ T cells in aviremic chronically infected patients is so far unknown. We report here a study 
indicating a higher efficiency of PI-based cART over NNRTI-based cART for limiting HIV-1 reactivation in 
CD4+ T cells from aviremic chronically HIV-1 infected patients.
Results
Forty-seven patients with chronic HIV-1 infection treated with cART (treatment range: 2 years to 16 years) 
and with undetectable plasma HIV-1 RNA levels (< 40 copies/ml) for at least 1 year were included in the study 
between 2008 and 2014. Of these 47 patients (mean age 47.4 years; range 27–93 years) treated with cART, 24 
were treated with PI-based cART and 23 with NNRTI-based cART (as their most recent treatment) for more 
than one year (Table 1, Supplementary Tables S1 and S2). We did not observe significant differences for nadir 
median CD4 counts (298·106 versus 333·106 cells/l, P = 0.579), median CD4 counts at initiation of treatment 
(384·106 versus 349·106 cells/l, P = 0·903), median CD4 counts at the last point (607·106 versus 624·106 cells/l, 
P = 0·647), and median HIV RNA load at zenith (4·92 versus 4·83 log/ml, P = 0·892) between PI-treated and 
NNRTI-treated patients (Table 1). We did not find significant differences between PI-treated and NNRTI-treated 
patients for the number of failures of treatment (1 versus 1, P = 0·985) and the duration of therapy (8·50 versus 
8·52 years, P = 0·936). The duration with undetectable plasma HIV-1 RNA levels was not significantly different in 
the PI-treated arm compared to the NNRTI-treated arm (4·83 versus 5·39 years, P = 0·581) (Table 1). At the last 
treatment, in 51·1% of individuals cART included a PI (fosamprenavir; saquinavir; atazanavir; lopinavir/ritona-
vir; darunavir) and in 48·9% a NNRTI (nevirapine; efavirenz; rilpivirine). Of note, among the 47 patients treated 
with cART, 17 were treated only with PI and 7 only with NNRTI (Supplementary Tables S1 and S2).
In order to evaluate the qualitative and quantitative patient-specific variations in the ex vivo reactivation 
capacity of the HIV-infected cells depending of cART treatment, we analyzed the effect of a known HIV inducer 
(anti-CD2+ anti-CD28 antibodies)15,16 on viral reactivation in ex vivo cultures of purified resting CD4+ T cells 
isolated from HIV+ patients treated with PI-based cART and with NNRTI-based cART. Since latently infected 
resting CD4+ T cells that harbour integrated replication-competent viral DNA represent the primary long-lived 
source of persistent HIV-1 in patients under cART5,6, we decided to analyze the impact of cART regimen on 
resting CD4+ T cells isolated from HIV+ patients. We observed, following reactivation of HIV-1 from latency 
in purified resting CD4+ T cells, that HIV-1 recovery was 0·92 log of HIV RNA copies/ml (3·01 versus 3·93 log 
copies/ml, P = 0·024) lower in HIV-1-infected patients treated with PI compared to those treated with NNRTI as 
their lastly administered treatment (Tables 1 and 2, and Fig. 1A). The impact of PI versus NNRTI treatment, tak-
ing into account the last treatment administered, on latently infected CD4+ T cells was further assessed by quan-
tifying integrated HIV-1 DNA. The levels of integrated HIV-1 DNA was 0·89 log (2·09 versus 2·98 log copies/106 
cells, P = 0·024) lower in purified resting CD4+ T cells isolated from HIV-1 patients treated with PI-based cART 
compared to HIV-1-infected patients treated with NNRTI-based cART (Tables 1 and 3, and Fig. 1B).
Discussion
To diminish the size of the viral reservoir, several studies have shown that an early treatment during HIV-1 
primo-infection could be beneficial13,14, and recently on-demand preexposure prohylaxis has been shown to be 
highly efficient to prevent HIV transmission17. We report here a study indicating that PI-based cART could be 
more efficient than NNRTI-based cART for limiting HIV-1 reactivation in aviremic chronically infected patients.
Although the respective use of NNRTI-based cART and PI-based cART have been extensively studied in 
regard to residual viremia, only little is known on their impact on cellular reservoirs of HIV-1. By two approaches, 
reactivation assay and the Alu-PCR assay that allow evaluating in a qualitative and quantitative manner, respec-
tively, the amount of integrated provirus, we observed that PI-based cART was superior to NNRTI-based cART 
for limiting the size of the HIV-1 reservoir. Recent studies indicate that raltegravir intensification of PI-based 
Biological characteristics
PI NNRTI P value
(n = 24) (n = 23)
Age (years), mean (± s.d.) 48.6 ± 12.7 46.2 ± 10.7 0.495
CD4+ T cell counts at nadir, absolute (cells per μ l), median (IQR) 298 (201–375) 333 (246–419) 0.579
CD4+ T cell counts at initiation of treatment, absolute (cells per μ l), median (IQR) 384 (285–461) 349 (265–574) 0.903
CD4+ T cell counts at the last point, absolute (cells per μ l), median (IQR) 607 (480–832) 624 (492–801) 0.647
pVL at zenith (log copies per ml), median (IQR) 4.92 (4.23–5.07) 4.83 (4.47–5.16) 0.892
Previous treatment failure, median (IQR) 1·00 (0–2.25) 1·00 (0–4) 0.985
Time with therapy (years), mean ± s.d. 8.50 ± 3.63 8.52 ± 3.49 0.936
Time with undetectable pVL (years), mean ± s.d. 4.83 ± 2.97 5.39 ± 2.73 0.581
HIV-1 reactivation assay
 Resting CD4+ T cells (n = 10) (n = 11)
 HIV-1 RNA levels after reactivation assay (log copies per ml), median (IQR) 3.01 (1.84–3.45) 3.93 (3.31–4.87) 0.024*
HIV-1 integration assay
 Resting CD4+ T cells (n = 14) (n = 12)
 Integrated HIV-1 DNA (log copies per 106 cells), median (IQR) 2.09 (1.53–2.52) 2.98 (2.55–3.48) 0.024*
Table 1.  Comparison of biological and virological characteristics of HIV+ patient groups under PI-cART 
and NNRTI-cART. IQR, interquartile range; pVL, plasma viral load *P < 0·05.
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cART results in a specific and transient increase in episomal HIV DNA that might represent lower efficiency of 
HIV integration under PI18,19. Recent publications also indicate that the size of the HIV-1 reservoir measured 
by total cell-associated HIV-1 DNA correlates positively with the frequency of positive recovery measurements 
in response to various latency-reversing agents20. Additionally, the low frequency of infected cells in the HIV-1 
Patients









HIV-1 RNA levels (years)
HIV-1 RNA levels 
after reactivation 
assay (copies/ml)
HIV-1 RNA levels 
after reactivation 
assay (log copies/ml)
PI at the last treatment (n = 10)
 WSH 229 617 ABC 3TC SQV 13 12 25862 4.41
 WSH 231 770 ABC 3TC ATV 10 7 40 1.60
 WSH 232 899 TDF FTC fAPV 7 1 3106 3.49
 WSH 233 465 ATV EFV 8 8 40 1.60
 WSH 235 797 DDI AZT 3TC fAPV 15 5 1108 3.04
 WSH 236 402 TDF FTC ATV 13 1 2862 3.46
 WSH 238 1240 TDF FTC ATV 5 5 40 1.60
 WSH 239 999 TDF FTC ATV 9 1 954 2.98
 WSH 240 663 TDF FTC ATV 9 4 2548 3.41
 WSH 241 524 TDF FTC fAPV 2 2 372 2.57
 Mean 738 9.10 4.60 3693 2.82
 SD 246 3.73 3.44 7477 0.91
 Median 717 9.00 4.50 1031 3.01
 1st Quartile 547 7.25 1.25 123 1.84
 3rd Quartile 874 12.3 6.50 2784 3.45
NNRTI at the last treatment (n = 11)
 WSH 227 733 EFV FTC TDF 9 8 146 2.16
 WSH 228 1324 TDF FTC NVP 10 7 229674 5.36
 WSH 230 444 EFV FTC TDF 8 1 8492 3.93




10 3 1668 3.22
 WSH 243 794 EFV FTC TDF 6 1 2514 3.40
 WSH 244 479 EFV FTC TDF 8 8 122268 5.09
 WSH 245 478 TDF FTC NVP 12 3 43614 4.64
 WSH 246 629 EFV FTC TDF 3 1 374578 5.57
 WSH 247 498 ABC 3TC NVP 16 7 31976 4.50
 WSH 248 1017 ABC 3TC EFV 10 7 4224 3.63
 WSH 249 519 AZT 3TC NVP 13 11 668 2.82
 Mean 668 9.55 5.18 74529 4.03
 SD 270 3.31 3.33 116748 1.05
 Median 519 10.0 7.00 8492 3.93
 1st Quartile 479 8.00 2.00 2091 3.31
 3rd Quartile 764 11.0 7.50 82941 4.87
 MW p-value 0.461 0.768 0.684 0.024 0.024
Table 2.  Reactivation assay on HLA DR− CD25− CD69− CD4+ T cells (resting CD4+ T cells) isolated 
from HIV+ patients with undetectable viremia treated with PI (n = 10) and NNRTI (n = 11) as their lastly 
administered treatment.
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controllers is associated with less efficient viral reactivation21. Our data are in line with these findings indicating 
that limited reactivation could be a consequence of lower integration events.
Several molecular mechanisms could explain the lower viral reactivation under PIs. First, low frequency 
of viral integration in transcriptionally active sites could explain the limited reactivation observed under PIs. 
Second, since integrase is produced by protease-mediated cleavage of the Pr160Gag-Pol precursor protein, PIs might 
inhibit HIV-1 integration by preventing the formation of a functional integrase19. Impaired integrase activity 
and/or impairment of the integrase-LEDGF/p75 interaction could result in a decreased number of integrated 
provirus in transcriptionally active sites, but also could favor the viral integration in less transcriptionally active 
sites which will result in lower viral reactivation22. Third, HIV PIs have been reported to block Akt activation23, 
and we recently observed that PIs, by blocking Akt activation especially triggered by Nef, limit HIV-1 recovery 
from latently-infected T cells24. Additionally HIV integration and the establishment of latency in CCL19-treated 
resting CD4+ T cells has been shown to require activation of NF-kB and increased HIV integrase stability25. 
Interestingly, PIs block NF-kB activation induced by Toll-like receptor 2 (TLR2) and TLR426. We also observed 
that PIs, but not NNRTIs, block Akt activation in PBLs treated with recombinant HIV-1 Nef in vitro and that the 
blockade of Nef-mediated Akt activation by Akt inhibitors decreased dramatically NF-kB activation24. Therefore, 
we cannot exclude that PIs by blocking HIV-mediated Akt activation in T cells decrease NF-kB activation and 
ultimately limit HIV integration in T cells.
Since Akt activation is critical for cell survival, the blockade of Akt activation by PIs in latently infected resting 
CD4+ T cells could help to clear these cells through accelerated cell death. Additionally, PIs have been shown to 
trigger the death of CD4+ T cells through the generation of Casp8p41, a fragment obtained by cleavage of pro-
caspase 8 by PIs, that lacks caspase activity but nonetheless contributes to T cell apoptosis27. Thus PIs could partic-
ipate to decrease the size of the viral reservoir in infected patients through the clearance of infected CD4+ T cells.
Low HIV-1 reservoirs found in HIV-1 controllers contributes to temporary control of infection without 
antiretroviral therapy21. Along this line, control of HIV-1 viremia or delayed viral rebound after discontinua-
tion of antiretroviral treatment has been consistently associated with low levels of cell associated HIV-DNA at 
the time of treatment interruption28,29. Therefore, lower levels of integrated HIV-1 in purified resting CD4+ T 
cells isolated from HIV-1 patients treated with PI-based cART compared to HIV-1-infected patients treated with 
NNRTI-based cART could be critical to achieve control of infection.
Figure 1. Resting CD4+ T cells isolated from PI-treated patients compared to NNRTI-treated patients 
showed a limited HIV-1 reactivation upon T-cell stimulation and a lower level of HIV-1 integration.  
(A) Comparison of reactivation assay on resting CD4+ T cells isolated from HIV+ patients with undetectable 
viremia treated with PI (n = 10) and NNRTI (n = 11) as their lastly administered treatment. (B) Comparison of 
measurement of integrated HIV-1 DNA in resting CD4+ T cells isolated from HIV+ patients with undetectable 
viremia treated with PI (n = 14) and NNRTI (n = 12) as their lastly administered treatment.
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In conclusion, in aviremic chronically HIV-1-infected patients our study indicates that PI-based cART limits HIV-1 
recovery from latently infected resting CD4+ T cells and curtails the amount of integrated HIV-1 DNA. Altogether, 
our results support the need to further assess the therapeutic use of HIV-1 protease inhibitors in view of their impact 
on persistence of HIV-1 reservoirs and might provide and/or accompany new therapeutic strategies for a remission.
Methods
Ethics approval and consent to participate. All the patients who were enrolled at the St-Pierre 
University Hospital (Brussels, Belgium) and the Besançon University Hospital (France) gave their written 
informed consent to participate in the study according to the Helsinki declaration. The study was approved by the 
local ethics committees of the Saint-Pierre University Hospital (Brussels, Belgium) and the Besancon University 
Hospital (Besançon, France) (CPP EST-2). To perform our study, we used blood samples that were part of a rou-
tine care. It was an observational study and not a clinical trial. According to the French Regulatory Authority for 
clinical studies, prospective and retrospective studies with observation analysis only are not evaluated by Human 
Protection Committees. The Human Protection Committee East Area II from France was consulted and issued a 
Patients
CD4+ at the last 





HIV-1 RNA levels (years)
Integrated HIV-1 DNA 
(copies/10^6 cells)
Integrated HIV-1 DNA 
(log copies/10^6 cells)
PI at the last treatment (n = 14)
 B9 485 TDF FTC ATV 11 8 95 1.97
 B13 512 ABC 3TC ATV 14 8 85 1.92
 B15 995 TDF FTC ATV 12 8 4731 3.67
 B27 529 ABC 3TC ATV 3 2 4 0.6
 B33 404 TDF FTC DRV 8 2 175 2.24
 B34 127 TDF FTC DRV 2 1 17 1.23
 B38 423 TDF FTC ATV 8 5 2 0.3
 B39 997 ABC 3TC DRV 8 3 409 2.61
 B40 394 fAPV AZT 3TC 8 5 56 1.74
 B41 596 TDF FTC DRV 3 2 29 1.46
 B42 638 DRV TDF ABC 3TC 8 5 307 2.48
 B43 505 ABC 3TC ATV 10 8 163 2.21
 B45 809 ABC TDF DRV 12 8 344 2.53
 B46 906 ABC 3TC ATV 6 5 635 2.8
 Mean 594 8.07 5.00 504 1.98
 SD 242 3.49 2.56 1186 0.85
 Median 521 8.00 5.00 129 2.09
 1st Quartile 439 6.50 2.25 35.8 1.53
 3rd Quartile 766 10.8 8.00 335 2.52
NNRTI at the last treatment (n = 12)
 B2 548 EFV FTC TDF 5 4 6174 3.79
 B3 927 ABC 3TC NVP 7 5 2 0.3
 B6 479 NVP TDF FTC 8 7 682 2.83
 B8 975 EFV FTC TDF 3 2 985 2.99
 B10 580 EFV TDF FTC 6 5 2963 3.47
 B14 486 NVP TDF FTC 5 4 944 2.97
 B16 928 TDF FTC NVP 15 8 2879 3.46
 B18 624 TDF FTC RPV 5 4 10218 4.01
 B21 607 TDF FTC RPV 12 8 49 1.69
 B22 793 TDF FTC NVP 5 4 38 1.58
 B29 807 TDF FTC RPV 10 8 3185 3.5
 B37 790 TDF FTC RPV 10 8 771 2.88
 Mean 712 7.58 5.58 2408 2.79
 SD 171 3.38 2.02 2931 1.04
 Median 707 6.50 5.00 965 2.98
 1st Quartile 572 5.00 4.00 524 2.55
 3rd Quartile 837 10.0 8.00 3019 3.48
 MW p-value 0.210 0.583 0.719 0.024 0.024
Table 3.  Measurement of integrated HIV-1 DNA in HLA DR− CD25− CD69− CD4+ T cells (resting CD4+ 
T cells) isolated from HIV+ patients with undetectable viremia treated with PI (n = 14) and NNRTI (n = 12) 
as their lastly administered treatment.
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formal waiver of approval. This study did not rely solely on medical records. The authors did not have any contact 
with the study subjects and performed tests on patient blood samples that were part of a routine care. The blood 
samples were anonymized before being used by the authors.
Patients. We enrolled 47 chronically HIV-1 infected individuals at the St-Pierre Hospital (Brussels, Belgium) 
and the Besançon University Hospital (Besançon, France). The patients were treated with cART (treatment 
range: 2 years to 16 years) and had undetectable plasma HIV-1 RNA levels (< 40 copies/ml) for at least 1 year. 
Characteristics of these patients were well documented and presented in Supplementary Tables S1 and S2. Of 
these 47 patients treated with cART, 24 were treated with PI and 23 with NNRTI as their most recent treatment 
for more than one year.
Isolation of resting CD4+ T lymphocytes. Purified CD25−, CD69−, HLA-DR− CD4+ T cells (resting 
CD4+ T cells) were obtained from the peripheral blood of HIV+ patients using a negative selection assay using 
magnetic beads (LD columns, Miltenyi Biotec, Bergisch Gladbach, Germany) as described previously30.
Viral reactivation assay. One day after isolation, 5 × 105 purified CD25−, CD69−, HLA-DR− CD4+ T cells 
(resting CD4+ T cells) were mock-treated or treated with anti-CD2+ anti-CD28 antibodies as a positive control 
for global T-cell activation15,16. For the measurement of reactivation of HIV-1 expression in resting CD4+ T cells 
isolated from the peripheral blood of HIV-infected patients, six days after treatment, culture supernatants were 
tested for quantitative HIV-1 RNA levels using the COBAS AmpliPrep/COBAS Amplicor HIV-1 Monitor Test, 
according to the manufacturer’s instructions.
Quantification of integrated HIV-1 DNA. Integrated HIV-1 DNA was measured by using a pre-
viously described Alu-gag PCR with some modifications31. This assay detects only integrated provirus 
because it relies on initial amplification in which one primer hybridizes with conserved sequences in Alu ele-
ments that are present in the human genome. The level of HIV-1 integration was measured by comparing 
the detection signal to an integration standard curve that was prepared from U1 cells. ACH2 cells were used 
for calibration. The sequences of first step PCR amplification primers were as follows: genomic Alu forward, 
5′ -GCCTCCCAAAGTGCTGGGATTACAG-3′ ; and HIV-1 gag reverse, 5′ -GCTCTCGCACCCATCTCTCTCC-3′ . 
The reaction conditions were 1x Tfi PCR reaction buffer, 1.5 mM MgCl2, 1 mM dNTPs, 100 nM Alu forward 
primer, 600 nM gag reverse primer and 5 U of Tfi DNA polymerase (Invitrogen). The thermal cycler (Eppendorf 
AG, Hamburg, Germany) was programmed to perform a 2 min hot start at 94 °C, followed by 20 cycles of fol-
lowing: denaturation at 94 °C for 30 sec, annealing at 50 °C for 1 min, and extension at 72 °C for 1 min 40 sec. 
The second round of real time quantitative PCR was performed using 21 μ l of Nested Alu-gag PCR along 
with standard curve amplification products. The sequences of the primers were as follows: LTR forward, 
5′ -GCCTCAATAAAGCTTGCCTTGA-3′ ; and LTR reverse, 5′ -TCCACACTGACTAAAAGGGTCTGA-3′ . The 
LTR Taqman probe, labeled at its 5′ terminus with the reporter fluorophore 6-carboxyfluorescein (FAM) and at its 3′ 
terminus with the quencher 4-(4-dimethylamino-phenylazo)-benzene (DABCYL), had the following sequence: 
5′ -FAM-GCGAGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGCTCGC-DABCYL-3′ . The reaction was car-
ried out in a volume of 50 μ l containing 1 X Taqman Master mix (Applied Biosystems, Foster City, CA), 250 nM 
concentration of LTR forward and reverse primers, and 200 nM Taqman probe. The reactions were performed on 
Stratagene Mx2005 P. The thermal program was 2 min hot start at 95 °C, followed by 40 cycles of denaturation at 
95 °C for 15 sec and annealing and extension at 60 °C for 1 min.
Data analysis. The program used for plotting and statistical analysis was Prism version 6.0 (GraphPad 
Software). Results from ex vivo reactivation studies and HIV integration using patient cell cultures of rest-
ing CD4+ T cells are shown as medians. Data sets were analyzed using an unpaired nonparametric t-test 
(Mann-Whitney test). Differences were considered significant at a value of p < 0.05.
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